The US National Institutes of Health acknowledges that some psychedelics are promising new therapies for patients with mental health challenges because they promote plasticity in the brain. For example, the activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT2ARs) is essential for Psychedelic-induced cortical plasticity. Ongoing work in this field includes mapping how changes in consciousness are linked to cortex-wide fluctuations in receptor density to identify patterns related to specific drug experiences